On Feb. 19, the U.S. Food and Drug Administration took a huge step towards patient-centric medicine when it approved the marketing of genetics testing company 23andMe’s carrier test for Bloom Syndrome. This was a startling — and good — development because it affirmed the rights of consumers to drive their own health-care decisions and procedures. But it also means that it has become urgent to develop policies to regulate the rights of companies to resell data derived from the contents of our DNA and from our medical records.
{iframe}http://www.washingtonpost.com/blogs/innovations/wp/2015/03/02/why-we-should-all-be-thrilled-about-the-fda-starting-to-embrace-innovation/{/iframe}